# DoW Breast Cancer, Transformative Breast Cancer Consortium Award

Source: https://welltoldgrants.com/grants/ht942526bcrptbcca-dow-breast-cancer-transformative-breast-cancer-consortium/  
Official notice: https://www.grants.gov/search-results-detail/362210

> Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make one award worth $35.0 million in total. Applications closed on September 30, 2026.

| Field | Value |
|---|---|
| Opportunity number | HT942526BCRPTBCCA |
| Agency | Defense Health Agency Contracting Activity - DHACA |
| Status | Forecast |
| Deadline | September 30, 2026 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 1 |
| Total funding | $35.0 million |
| Cost sharing | not required |
| Assistance Listings | 12.420 |

## Who can apply

- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

## What the grant funds

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Award supports collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer. Applications must propose a synergistic, highly integrated, multidisciplinary and multi-institutional consortium of leading scientists, clinicians and breast cancer consumer advocates that will address a major problem in a way that a single investigator or group could not accomplish. The consortium’s collaborative efforts must make a transformative impact in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. If the application addresses a different fundamental issue, the application must couple it with at least one of the overarching challenges. Distinctive Features: This funding mechanism allows for up to five Principal Investigators (PIs) which includes the Consortium Director and three or four Project Team PIs. Applications must include at least one breast cancer consumer advocate per project team. Only the Consortium Director will submit a pre-application, but all PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Consortium Director and Project Team PIs) applications by the full application deadline may result in administrative withdrawal.

## Questions people ask

### Is HT942526BCRPTBCCA still open?

No. It closed on September 30, 2026. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).

### Who can apply for DoW Breast Cancer, Transformative Breast Cancer Consortium Award?

Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.

### What is the deadline for DoW Breast Cancer, Transformative Breast Cancer Consortium Award?

Closed September 30, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

About $35.0 million in total for one award.

### Who has won Military Medical Research and Development grants before?

The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.